1
|
Wolzak K, Vermunt L, Campo MD, Jorge-Oliva M, van Ziel AM, Li KW, Smit AB, Chen-Ploktkin A, Irwin DJ, Lemstra AW, Pijnenburg Y, van der Flier W, Zetterberg H, Gobom J, Blennow K, Visser PJ, Teunissen CE, Tijms BM, Scheper W. Protein disulfide isomerases as CSF biomarkers for the neuronal response to tau pathology. Alzheimers Dement 2023; 19:3563-3574. [PMID: 36825551 DOI: 10.1002/alz.12978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 10/06/2021] [Accepted: 01/13/2023] [Indexed: 02/25/2023]
Abstract
INTRODUCTION Cerebrospinal fluid (CSF) biomarkers for specific cellular disease processes are lacking for tauopathies. In this translational study we aimed to identify CSF biomarkers reflecting early tau pathology-associated unfolded protein response (UPR) activation. METHODS We employed mass spectrometry proteomics and targeted immunoanalysis in a combination of biomarker discovery in primary mouse neurons in vitro and validation in patient CSF from two independent large multicentre cohorts (EMIF-AD MBD, n = 310; PRIDE, n = 771). RESULTS First, we identify members of the protein disulfide isomerase (PDI) family in the neuronal UPR-activated secretome and validate secretion upon tau aggregation in vitro. Next, we demonstrate that PDIA1 and PDIA3 levels correlate with total- and phosphorylated-tau levels in CSF. PDIA1 levels are increased in CSF from AD patients compared to controls and patients with tau-unrelated frontotemporal and Lewy body dementia (LBD). HIGHLIGHTS Neuronal unfolded protein response (UPR) activation induces the secretion of protein disulfide isomerases (PDIs) in vitro. PDIA1 is secreted upon tau aggregation in neurons in vitro. PDIA1 and PDIA3 levels correlate with total and phosphorylated tau levels in CSF. PDIA1 levels are increased in CSF from Alzheimer's disease (AD) patients compared to controls. PDIA1 levels are not increased in CSF from tau-unrelated frontotemporal dementia (FTD) and Lewy body dementia (LBD) patients.
Collapse
Affiliation(s)
- Kimberly Wolzak
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
| | - Lisa Vermunt
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Marta Del Campo
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo- CEU, CEU Universities, Madrid, Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
| | - Marta Jorge-Oliva
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
| | - Anna Maria van Ziel
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
| | - Ka Wan Li
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - August B Smit
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Alice Chen-Ploktkin
- Department of Neurology, Perelman school of medicine, University of Pennsylvania, Philadelphia, USA
| | - David J Irwin
- Department of Neurology, Perelman school of medicine, University of Pennsylvania, Philadelphia, USA
- Penn Frontotemporal Degeneration Center, Perelman school of medicine, University of Pennsylvania, Philadelphia, USA
| | - Afina W Lemstra
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Yolande Pijnenburg
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Wiesje van der Flier
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Department of Epidemiology and Data Science, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute at UCL, London, UK
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
| | - Johan Gobom
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Pieter Jelle Visser
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden
| | - Charlotte E Teunissen
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Betty M Tijms
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
| | - Wiep Scheper
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) location Vrije Universiteit, Amsterdam, the Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
| |
Collapse
|
2
|
Wolzak K, Nölle A, Farina M, Abbink TE, van der Knaap MS, Verhage M, Scheper W. Neuron-specific translational control shift ensures proteostatic resilience during ER stress. EMBO J 2022; 41:e110501. [PMID: 35791631 PMCID: PMC9379547 DOI: 10.15252/embj.2021110501] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 06/06/2022] [Accepted: 06/09/2022] [Indexed: 11/30/2022] Open
Abstract
Proteostasis is essential for cellular survival and particularly important for highly specialised post‐mitotic cells such as neurons. Transient reduction in protein synthesis by protein kinase R‐like endoplasmic reticulum (ER) kinase (PERK)‐mediated phosphorylation of eukaryotic translation initiation factor 2α (p‐eIF2α) is a major proteostatic survival response during ER stress. Paradoxically, neurons are remarkably tolerant to PERK dysfunction, which suggests the existence of cell type‐specific mechanisms that secure proteostatic stress resilience. Here, we demonstrate that PERK‐deficient neurons, unlike other cell types, fully retain the capacity to control translation during ER stress. We observe rescaling of the ATF4 response, while the reduction in protein synthesis is fully retained. We identify two molecular pathways that jointly drive translational control in PERK‐deficient neurons. Haem‐regulated inhibitor (HRI) mediates p‐eIF2α and the ATF4 response and is complemented by the tRNA cleaving RNase angiogenin (ANG) to reduce protein synthesis. Overall, our study elucidates an intricate back‐up mechanism to ascertain translational control during ER stress in neurons that provides a mechanistic explanation for the thus far unresolved observation of neuronal resilience to proteostatic stress.
Collapse
Affiliation(s)
- Kimberly Wolzak
- Department of Functional Genomics, Faculty of Science, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands.,Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| | - Anna Nölle
- Department of Pathology, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| | - Margherita Farina
- Department of Functional Genomics, Faculty of Science, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands
| | - Truus Em Abbink
- Department of Child Neurology, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| | - Marjo S van der Knaap
- Department of Functional Genomics, Faculty of Science, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands.,Department of Child Neurology, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| | - Matthijs Verhage
- Department of Functional Genomics, Faculty of Science, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands.,Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| | - Wiep Scheper
- Department of Functional Genomics, Faculty of Science, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands.,Functional Genomics Section, Department of Human Genetics, Amsterdam University Medical Centers (UMC) Location Vrije Universiteit, Amsterdam, The Netherlands
| |
Collapse
|
3
|
van Ziel AM, Wolzak K, Nölle A, Hoetjes PJ, Berenjeno-Correa E, van Anken E, Struys EA, Scheper W. No evidence for cell-to-cell transmission of the unfolded protein response in cell culture. J Neurochem 2019; 152:208-220. [PMID: 31442299 PMCID: PMC7003778 DOI: 10.1111/jnc.14856] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 07/31/2019] [Accepted: 08/12/2019] [Indexed: 12/18/2022]
Abstract
The unfolded protein response (UPR) is one of the major cell‐autonomous proteostatic stress responses. The UPR has been implicated in the pathogenesis of neurodegenerative diseases and is therefore actively investigated as therapeutic target. In this respect, cell non‐autonomous effects of the UPR including the reported cell‐to‐cell transmission of UPR activity may be highly important. A pharmaca‐based UPR induction was employed to generate conditioned media (CM) from CM‐donating neuronal (‘donor’) cells (SK‐N‐SH and primary mouse neurons). As previously reported, upon subsequent transfer of CM to naive neuronal ‘acceptor’ cells, we confirmed UPR target mRNA and protein expression by qPCR and automated microscopy. However, UPR target gene expression was also induced in the absence of donor cells, indicating carry‐over of pharmaca. Genetic induction of single pathways of the UPR in donor cells did not result in UPR transmission to acceptor cells. Moreover, no transmission was detected upon full UPR activation by nutrient deprivation or inducible expression of the heavy chain of immunoglobulin M in donor HeLa cells. In addition, in direct co‐culture of donor cells expressing the immunoglobulin M heavy chain and fluorescent UPR reporter acceptor HeLa cells, UPR transmission was not observed. In conclusion, carry‐over of pharmaca is a major confounding factor in pharmaca‐based UPR transmission protocols that are therefore unsuitable to study cell‐to‐cell UPR transmission. In addition, the absence of UPR transmission in non‐pharmaca‐based models of UPR activation indicates that cell‐to‐cell UPR transmission does not occur in cell culture. ![]()
Collapse
Affiliation(s)
- Anna M van Ziel
- Department of Clinical Genetics, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands.,Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Kimberly Wolzak
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Anna Nölle
- Department of Pathology, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands
| | - Petrus J Hoetjes
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Ernesto Berenjeno-Correa
- Department of Clinical Genetics, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands.,Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Eelco van Anken
- Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy
| | - Eduard A Struys
- Department of Clinical Chemistry, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands
| | - Wiep Scheper
- Department of Clinical Genetics, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands.,Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands.,Alzheimer Center, Amsterdam University Medical Centers Location VUmc, Amsterdam, The Netherlands
| |
Collapse
|
4
|
van Ziel AM, Largo-Barrientos P, Wolzak K, Verhage M, Scheper W. Unconventional secretion factor GRASP55 is increased by pharmacological unfolded protein response inducers in neurons. Sci Rep 2019; 9:1567. [PMID: 30733486 PMCID: PMC6367349 DOI: 10.1038/s41598-018-38146-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 12/19/2018] [Indexed: 12/18/2022] Open
Abstract
Accumulation of misfolded proteins in the endoplasmic reticulum (ER), defined as ER stress, results in activation of the unfolded protein response (UPR). UPR activation is commonly observed in neurodegenerative diseases. ER stress can trigger unconventional secretion mediated by Golgi reassembly and stacking proteins (GRASP) relocalization in cell lines. Here we study the regulation of GRASP55 by the UPR upon pharmacological induction of ER stress in primary mouse neurons. We demonstrate that UPR activation induces mRNA and protein expression of GRASP55, but not GRASP65, in cortical neurons. UPR activation does not result in relocalization of GRASP55. UPR-induced GRASP55 expression is reduced by inhibition of the PERK pathway of the UPR and abolished by inhibition of the endonuclease activity of the UPR transducer IRE1. Expression of the IRE1 target XBP1s in the absence of ER stress is not sufficient to increase GRASP55 expression. Knockdown of GRASP55 affects neither induction nor recovery of the UPR. We conclude that the UPR regulates the unconventional secretion factor GRASP55 via a mechanism that requires the IRE1 and the PERK pathway of the UPR in neurons.
Collapse
Affiliation(s)
- Anna Maria van Ziel
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands.,Clinical Genetics, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands
| | - Pablo Largo-Barrientos
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Kimberly Wolzak
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands
| | - Matthijs Verhage
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands.,Clinical Genetics, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands
| | - Wiep Scheper
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit (VU), Amsterdam, The Netherlands. .,Clinical Genetics, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands. .,Alzheimer Center, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
| |
Collapse
|